Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine

Clinical Neuropharmacology

Volumn 36, Issue 6, 2013, Pages 198-202

  Terhardt, Johannes ^a,b   Lederbogen, Florian ^a   Feuerhack, Anne ^a   Hamann Weber, Bettina ^a   Gilles, Maria ^a   Schilling, Claudia ^a   Lecei, Olivera ^a   Deuschle, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

autonomous nervous system; catecholamine; ECG; heart rate variability; noradrenaline

Indexed keywords

LORAZEPAM; MIRTAZAPINE; VENLAFAXINE; ZOLPIDEM;

ADULT; ARTICLE; BODY MASS; CARDIOTACHOMETER; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HEART RATE; HEART RATE VARIABILITY; HUMAN; MAJOR DEPRESSION; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REST; STANDING; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84888128468     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182a76fbb     Document Type: Article

References (47)

1. Lespérance F, Frasure-Smith N, Talajic M BM. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002;105(9):1049-1053.
2. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003;54(3):241-247.
3. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66(6):802-813.
4. Wulsin LR, Singal B. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003;65(2):201-210.
5. Thakore JH, Richards PJ, Reznek RH, et al. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997;41(11):1140-1142.
6. Weber-Hamann B, Kopf D, Lederbogen F, et al. Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology 2005;81(3):200-204.
7. Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients. J Clin Psychopharmacol 2004;24(5):527-531.
8. Bruce EC, Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 2005;67(9)(suppl 1):S34-S36.
9. Rosenwinkel ET, Bloomfield DM, Arwady MA, et al. Exercise and autonomic function in health and cardiovascular disease. Cardiol Clin 2001;19(3):369-387.
10. Eisenhofer G, Friberg P, Goldstein DS, et al. Differential actions of desipramine on sympathoadrenal release of noradrenaline and adrenaline. Br J Clin Pharmacol 1995;40:263-265.
11. Lecei O, Lederbogen F, GronauW, et al. Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients. J Clin Psychopharmacol 2012;32(4):574-576.
12. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986;59(2):178-193.
13. Akselrod S, Gordon D, Ubel FA, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981;213:220-222.
14. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85(1):164-171.
15. Dekker JM, Crow RS, Folsom AR, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality. Circulation 2000 Sept 12;102(11):1239-44.
16. Carney RM, Freedland KE, Stein PK, et al. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med 2000;62(5):639-647.
17. Carney RM, Blumenthal JA, Freedland KE, et al. Low heart rate variability and the effect of depression on post-myocardial infarction mortality. Arch Intern Med 2005;165(13):1486-1491.
18. Kemp AH, Quintana DS, Gray MA, et al. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry 2010;67(11):1067-1074.
19. Scharnholz B, Weber-Hamann B, Lederbogen F, et al. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial. Psychiatry Res 2010;177(1-2):109-113.
20. Taylor CB. Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol 2010;78(1):80-88.
21. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009;12(1):1-21.
22. Moser M, Lehofer M, Hoehn-Saric R, et al. Increased heart rate in depressed subjects in spite of unchanged autonomic balance? J Affect Disord 1998;48(2-3):115-124.
23. Nahshoni E, Aravot D, Aizenberg D, et al. Heart rate variability in patients with major depression. Psychosomatics 2004;45(2):129-34.
24. Lampert R. Anger and ventricular arrhythmias. Curr Opin Cardiol 2010;25(1):46-52.
25. Electrophysiology Task force of the European Society of cardiology the north american society of pacing electrophysiology Heart rate variability: standards of measurements, physiological interpretations, and clinical use. Circulation 1996;93:1043-1065.
26. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438):937-952.
27. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001 Oct 23;104(17):2024-8.
28. Otte C, Neylan TC, Pipkin SS, et al. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2009;162(11):2139-2145.
29. Licht CMM, de Geus EJC, van Dyck R, et al. Association between anxiety disorders and heart rate variability in The Netherlands Study of Depression and Anxiety (NESDA). Psychosom Med 2009;71(5):508-518.
30. Rechlin T, Claus D, Weis M. Heart rate analysis in 24 patients treated with 150 mg amitriptyline per day. Psychopharmacology 1994;116 (1):110-114.
31. Bär K-J, Greiner W, Jochum T, et al. The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord 2004;82(2):245-252.
32. Leftheriotis D, Flevari P, Ikonomidis I, et al. The role of the selective serotonin re-uptake inhibitor sertraline in nondepressive patients with chronic ischemic heart failure: a preliminary study. Pacing Clin Electrophysiol 2010;33(10):1217-1223.
33. McFarlane A, Kamath MV, Fallen EL, et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001;142(4):617-623.
34. Lederbogen F, Gernoth C, Weber B, et al. Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability. J Clin Psychopharmacol 2001;21:238-239.
35. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279(4):287-291.
36. Pohl R, Balon R, Jayaraman A, et al. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. J Psychosom Res 2003;55(3):247-251.
37. Tulen JHM, Bruijn JA, de Man KJ, et al. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol 1996;16:135-145.
38. Davidson J, Watkins L, Owens M, et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol 2005;25(5):480-484.
39. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294.
40. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-508.
41. Stephen Waring W, Good AM, Nicholas Bateman D. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila) 2007;45(1):45-50.
42. Nahshoni E, Aizenberg D, Sigler M, et al. Heart rate variability increases in elderly depressed patients who respond to electroconvulsive therapy. J Psychosom Res 2004;56:89-94.
43. Schüle C, Baghai TC, Eser D, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology 2006;186(4):601-611.
44. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 2007;19(3):213-226.
45. McLeod DR, Hoehn-sarie R, Porges SW, et al. Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder. Psychopharmacology 1992;107:535-540.
46. Agelink MW, Majewski TB, Andrich J, et al. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med 2002;30(5):997-1006.
47. Chen HY, Kuo TB, Shaw FZ, et al. Sleep-related vagotonic effect of zolpidem in rats. Psychopharmacology (Berl) 2005;181(2):270-279.